ASLAN Pharmaceuticals, a leading biopharmaceutical company, recently announced plans to change the ratio of its American Depositary Shares (ADSs) to ordinary shares.This change, from one ADS representing twenty-five ordinary shares to one ADS representing two hundred ordinary shares, has significant implications for shareholders and the overall stock price.
This development comes on the heels of ASLAN Pharmaceuticals’ previous announcement of a $5 million registered direct offering, where the company sold 5,000,000 ADSs at an offering price of $1.00 per ADS.Additionally, the company issued warrants to purchase up to 5,000,000 ADSs in a concurrent private placement.
The impact of these recent news can be seen in ASLAN Pharmaceuticals Limited’s current share price of $0.4011, representing an 89.46% drop from the previous year.Shareholders will need to carefully consider how the adjusted ADS ratio will affect their investment in the company.
Overall, these developments signal a period of change and potential growth for ASLAN Pharmaceuticals.Investors will be closely watching how these strategic decisions shape the company’s future trajectory and market performance.
Comments